Paving a way to treat spastic paraplegia 50
Spastic paraplegia 50 (SPG50) is a rare neurodegenerative disease caused by loss-of-function mutations in AP4M1. There are no effective treatments for SPG50 or any other type of SPG, and current treatments are limited to symptomatic management. In this issue of the JCI, Chen et al. provide promising...
Main Authors: | Jonathan R. Brent, Han-Xiang Deng |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Clinical Investigation
2023-05-01
|
Series: | The Journal of Clinical Investigation |
Online Access: | https://doi.org/10.1172/JCI170226 |
Similar Items
-
Hereditary Spastic Paraplegia: An Update
by: Arun Meyyazhagan, et al.
Published: (2022-02-01) -
Movement disorders in hereditary spastic paraplegias
by: Jose Luiz Pedroso, et al.
Published: (2023-11-01) -
Clinical features and management of hereditary spastic paraplegia
by: Ingrid Faber, et al.
Published: (2014-03-01) -
Lysosome Function and Dysfunction in Hereditary Spastic Paraplegias
by: Daisy Edmison, et al.
Published: (2021-01-01) -
ER Morphology in the Pathogenesis of Hereditary Spastic Paraplegia
by: Sonia Sonda, et al.
Published: (2021-10-01)